佰诺创因可以利用自有技术平台，快速用大肠杆菌、酵母菌、293细胞，CHO细胞快速制备研究用蛋白、质粒、AAV、AdV，支持客户药物研发项目快速推进至CMC/IND/BLA阶段。

Transgenbio can leverage its proprietary technical platform to swiftly deliver research-grade proteins, plasmid,AAV, and Adv utilizing Escherichia coli, yeast, 293 cells, and CHO cells. This support aids in the rapid advancement of customers' drug R&D projects to the CMC/IND/BLA stage.